Please assess the completion status of the following clinical trial:

Trial Title: Measuring Smoking Behaviors While Using Varenicline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* self report minimum 10 daily cigarettes~* self report smoking every day past 5 years~* between the ages 21-65~* self report intention to try to quit smoking in the next 6 months~Exclusion Criteria:~* self reported use of any nicotine-containing products other than non-menthol cigarettes~* self reported history or current treatment of substance abuse (other than nicotine dependence)~* self reported alcohol use greater than 25 standard drinks per week;~* currently pregnant, planned pregnancy or lactating (females: negative urine pregnancy screen)~* self reported history or current diagnosis of any Axis 1 disorders except past depression~* self reported serious or unstable disease within past year~* self reported history of epilepsy or seizure disorder;~* self reported history or current diagnosis of COPD (chronic obstructive pulmonary disease), cardiovascular disease, heart attack, or uncontrolled hypertension~* self reported kidney function impairment~* any current or recent (30 day) use of: smoking cessation medications, anti-psychotics, anti-depressants, anti-anxiety, panic medications, stimulants or opiate-containing medications~* less than 5 years of daily smoking~* any medical condition or concomitant medication that could compromise participant safety or treatment~* provide a baseline carbon monoxide (CO) reading \< 10 ppm~* self reported use of non filtered cigarettes~* inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Varenicline before placebo (Type: EXPERIMENTAL): Drug (Varenicline (Chantix)): Placebo~Intervention to be administered is: participants will receive standard dosing regimen of Varenicline for 21 days total, followed by 14-day washout and 21 days of placebo. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.
- Placebo then Varenicline (Type: EXPERIMENTAL): Placebo: Drug Varenicline (Chantix)~Intervention to be administered is: participants will receive 21 days of placebo, followed by 14-day washout and standard dosing regimen of Varenicline for 21 days total. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.~Intervention 'Drug (Varenicline (Chantix)): Placebo'

Based on this trial design, predict the completion outcome and termination type (if applicable).